Skip to main content

25-01-2021 | COVID-19 | Podcast | Article

Repurposing rheumatology drugs for COVID-19: JAK inhibitors

Speaker: Marwan Bukhari

In this series of podcasts we are speaking to the experts about repurposing rheumatology drugs for the treatment and prevention of COVID-19. 

In this episode, we discuss JAK inhibitors with Marwan Bukhari, a rheumatologist from the University Hospitals of Morecambe Bay NHS Trust in the UK. He outlines the rationale for investigating these agents, the currently available efficacy data, and the aims of the ongoing TACTIC-R trial.

Listen below or subscribe to this Podcast on:

Google PodcastsApple Podcasts | SpotifyStitcher | TuneIn

About the speaker

Marwan Bukhari

Marwan Bukhari MBBS, MSc, FRCP, PhD, MAcadMEd is a consultant rheumatologist at the University Hospitals of Morecambe Bay NHS Trust and an honorary senior lecturer at Manchester University.

Full biography

Related topics

Repurposing rheumatology drugs for COVID-19

Experts discuss the rationale, data on different agents, and the potential impact on rheumatology practice.

  • » Featuring insights from the COVID-19 Global Rheumatology Alliance, EULAR, and the Lupus Foundation of America
Image Credits